Case Study: How Pharma Uses NeoGenomics Real-World Oncology Data to Accelerate Biomarker Adoption and Commercial Launch
Blog
Read More
NeoGenomics Provides Update on MolDX Submission for CRC and RaDaR(TM) Commercial Launch
Press Release
Read More
NeoGenomics announces speaker program, ‘Minimal Residual Disease in Colorectal Cancer’
Blog
Read More
NeoGenomics Schedules its Third Quarter 2022 Earnings Release for November 8, 2022
Press Release
Read More
Liquid biopsy for detection of molecular residual disease and recurrence in head and neck squamous cell carcinoma
Literature
Read More